Insider filing · ZBIO

Hongbo Lu bought $1.5M of Zenas BioPharma (ZBIO)

Executed Mar 31, disclosed Mar 31, the same day.

Over the 21 trading sessions from the disclosed entry session (Mar 31), the stock returned -6.0% (delay-adjusted); from the execution session (Mar 31), -6.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

HL Hongbo Lu Director profile →

Hongbo Lu (Director) filed 4 Form 4 reports in the trailing twelve months (3 purchases, 1 sale, 1 filed past the two-business-day deadline), most often in Zenas BioPharma, Inc. (ZBIO). Across 3 priced purchase filings, the average 21-session return was +1.6% from execution and +2.9% from disclosure (delay-adjusted; derived). The largest single filing was $1.5M of ZBIO (75,000 sh × $20.00, as filed), executed Mar 31.

ZBIO Zenas BioPharma, Inc. ZBIO · Healthcare · 18 filings in 24 months ticker →

Healthcare · Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-ba…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→